Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anne Vaslin Chessex
Observed names:
A Vaslin Chessex,
A. Vaslin Chessex,
A.V. Chessex,
Anne V. Chessex
Institution:
OM Pharma (Switzerland)
Observed institutions:
Debiopharm (Switzerland),
OM Pharma (Switzerland)
OpenAlex ID:
A5002234759
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022
·
Daniel Zingg
, Jinhyuk Bhin
, et al.
·
Nature
·
133
PDF
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
2019
·
Martin H. Voss
, Cinta Hierro
, et al.
·
Clinical Cancer Research
·
124
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
2021
·
James M. Cleary
, Srivatsan Raghavan
, et al.
·
Cancer Discovery
·
116
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers
2022
·
Daniel Zingg
, Jinhyuk Bhin
, et al.
·
Nature
·
17
PDF
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
2017
·
Maximilien Murone
, Ramin Radpour
, et al.
·
Molecular Cancer Therapeutics
·
14
Abstract 4423: Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123
2019
·
Colin O'Dowd
, Gerald Gavory
, et al.
·
Cancer Research
·
11
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
2016
·
Maximilien Murone
, Anne Vaslin Chessex
, et al.
·
Molecular Cancer Therapeutics
·
8
Abstract 4703: The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in vivo
2018
·
Antoine Attinger
, Bruno Gavillet
, et al.
·
Cancer Research
·
7
Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results
2019
·
I. Matos
, L. Goyal
, et al.
·
Annals of Oncology
·
4
Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice
2026
·
Sabine Wronski
, Helena Obernolte
, et al.
·
Antiviral Research
·
2
Coupling A Quantitative Systems Pharmacology Model With A Simple Statistical Layer To Predict Asthma Exacerbation Rate Reduction From Allergen Challenge Results
2024
·
Simon Arsène
, Théo Galland
, et al.
·
1
PDF
Preclinical activity of Debio 1347, an oral selective FGFR1, 2, 3 inhibitor, in models harboring FGFR alterations
2014
·
A. Vaslin Chessex
, C. Moulon
, et al.
·
European Journal of Cancer
·
1
Expanding a Mechanistic Model of Recurrent Respiratory Infections in At-risk Populations: From Children to COPD and Elderly
2025
·
C. Sansone
, H. Darré
, et al.
·
American Journal of Respiratory and Critical Care Medicine
The bacterial lysate OM-85 mitigates HDM-induced allergic inflammation through airway epithelial cell- macrophage crosstalk
2025
·
Athanasios Kouklas
, Aurélien Trompette
, et al.
Abstract 6507: Simulation driven identification of combinations for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo
2024
·
Boldizsar Elek
, Anne V. Chessex
, et al.
·
Cancer Research
Assessing the oral bacterial lysate OM-85 to prevent viral respiratory infection following irradiation and bone marrow transplantation.
2024
·
C Pasquali
, K Landwehr
, et al.
·
ERS Lung Science Conference
Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials
2024
·
Cristhyne León
, Théo Galland
, et al.
PDF
Abstract 4423: Antitumor activity of the novel oral highly selective Wee1 inhibitor Debio 0123
2019
·
Colin O'Dowd
, Gerald Gavory
, et al.
·
Molecular and Cellular Biology / Genetics
Show more works
View as search
Works count:
53
Citation count:
438
H-index:
7
I10-index:
6
Year
Topic
Type